Protagonist Therapeutics, Inc Payments to Acquire Available-for-sale Securities
Protagonist Therapeutics, Inc (PTGX) reported Payments to Acquire Available-for-sale Securities of $21.73 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2019-05-08
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for the quarter ending 2019-03-31 was $21.73M, a 15.25% decline year-over-year.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for the quarter ending 2018-12-31 was $19.11M, a 67.78% increase year-over-year.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $12.94M, a 35.81% decline year-over-year.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $13.38M.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for fiscal 2018 was $71.06M, a 79.69% increase from fiscal 2017.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for fiscal 2017 was $39.55M, a 45.95% decline from fiscal 2016.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for fiscal 2016 was $73.17M, a 830.31% increase from fiscal 2015.
- Protagonist Therapeutics, Inc payments to acquire available-for-sale securities for fiscal 2015 was $7.87M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2019-03-31 | $21.73M 10-Q · filed 2019-05-08 | $40.84M derived: sum of 2 quarters · filed 2019-05-08 | $53.77M derived: sum of 3 quarters · filed 2019-05-08 | $67.15M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | $19.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $32.05M derived: sum of 2 quarters · filed 2019-03-12 | $45.42M derived: sum of 3 quarters · filed 2019-03-12 | $71.06M 10-K · filed 2019-03-12 |
| 2018-09-30 | $12.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $26.31M derived: sum of 2 quarters · filed 2018-11-06 | $51.95M 10-Q · filed 2018-11-06 | $63.34M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-06-30 | $13.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $39.01M 10-Q · filed 2018-08-07 | $50.40M derived: sum of 3 quarters · filed 2019-05-08 | $70.56M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-03-31 | $25.64M 10-Q · filed 2019-05-08 | $37.03M derived: sum of 2 quarters · filed 2019-05-08 | $57.18M derived: sum of 3 quarters · filed 2019-05-08 | $57.18M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $11.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $31.54M derived: sum of 2 quarters · filed 2019-03-12 | $31.54M derived: sum of 3 quarters · filed 2019-03-12 | $39.55M 10-K · filed 2019-03-12 |
| 2017-09-30 | $20.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $20.15M derived: sum of 2 quarters · filed 2018-11-06 | $28.15M 10-Q · filed 2018-11-06 | $94.93M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $8.00M 10-Q · filed 2018-08-07 | $74.78M derived: sum of 3 quarters · filed 2019-03-12 | $74.78M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $8.00M 10-Q · filed 2018-05-09 | $74.78M derived: sum of 2 quarters · filed 2019-03-12 | $74.78M derived: sum of 3 quarters · filed 2019-03-12 | $81.17M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $66.77M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $66.77M derived: sum of 2 quarters · filed 2019-03-12 | $73.17M derived: sum of 3 quarters · filed 2019-03-12 | $73.17M 10-K · filed 2019-03-12 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.40M derived: sum of 2 quarters · filed 2017-11-07 | $6.40M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $6.40M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $7.87M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |